Skip to search formSkip to main contentSkip to account menu

imiquimod

Known as: 4-Amino-1-isobutyl-1H-imidazo(4,5-c)quinoline, imiquimod [Chemical/Ingredient], Imiquimodum 
A synthetic agent with immune response modifying activity. As an immune response modifier (IRM), imiquimod stimulates cytokine production, especially… 
National Institutes of Health

Related topics

Related topics

13 relations

Narrower (4)

AldaraR 837S 26308Zyclara

Broader (4)

AminoquinolinesAntineoplastic AgentsImmunologic AdjuvantsInterferon Inducers
Condylomata AcuminataDrug AllergyNCIt Antineoplastic Agent Terminologyimiquimod 50 MG/ML Topical Cream

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Characterization of bovine Toll-like receptor 8: ligand specificity, signaling essential sites and dimerization.
Highly Cited
2008
Highly Cited
2008
The duck toll like receptor 7: genomic organization, expression and function.
Highly Cited
2004
Highly Cited
2004
Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod
Lentigo maligna (LM) is an in situ melanoma which usually occurs in sun‐damaged skin on the head and neck of elderly patients… 
Review
2004
Review
2004
Current management strategies for cutaneous T-cell lymphoma.
Highly Cited
2003
Highly Cited
2003
Imiquimod Induces Complete Clearance of a PUVA-Resistant Plaque in Mycosis fungoides
Imiquimod is a topical immune response modifier that binds to Toll-like receptors 7 and 8 and induces α-interferon. We locally… 
Highly Cited
2002
Highly Cited
2002
Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study.
OBJECTIVE To investigate the efficacy of topical treatment with imiquimod 5% cream, an immune response modifier, in patients with… 
Review
2002
Review
2002
Imiquimod; an international update on therapeutic uses in dermatology
Imiquimod, the first member of a new class of immune response modifiers, is approved for the treatment of external genital and… 
Highly Cited
2000
Highly Cited
2000
The Use of Imiquimod 5% Cream for the Treatment of Superficial Basal Cell Carcinomas in a Basal Cell Nevus Syndrome Patient
Background. Imiquimod 5% cream has been used effectively to treat superficial basal cell carcinomas (BCCs). Objective. The… 
Highly Cited
1999
Highly Cited
1999
A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group.
OBJECTIVE To assess the safety of imiquimod, an immune response modifier, in the topical treatment of external anogenital warts… 
Review
1997
Review
1997
Therapeutic approaches to papillomavirus infections.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)